Loading...
Loading...
PharmAthene, Inc.
PIP today announced additional development progress of its next generation rPA anthrax vaccine, SparVax™, which is being developed to provide protection against anthrax exposure during a national security emergency.
Following on the successful cGMP manufacturing of SparVax™ at full commercial scale, the Company has now completed final analytical testing and release of the final drug product in pre-filled syringes for future clinical evaluation.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in